This strategy has been first applied to IBD, where the intragastric administration of a genetically engineered L. lactis strain producing an anti-inflammatory cytokine, the interleukin-10 (IL-10), caused a significant reduction in colitis in mice treated with DSS [31]. This evidence concerns the gene IL10 and inflammatory bowel disease.